HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 280, Issue 51, 42198-42206, December 23, 2005

This Article Full Text Full Text (PDF) All Versions of this Article: 280/51/42198    most recent M510180200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robert, J. Articles by Clauser, E. Search for Related Content PubMed PubMed Citation Articles by Robert, J. Articles by Clauser, E. Social Bookmarking                      What's this?

Mechanisms of Cell-surface Rerouting of an Endoplasmic Reticulum-retained Mutant of the Vasopressin V1b/V3 Receptor by a Pharmacological Chaperone^*

From the Institut Cochin, Département d'Endocrinologie, Paris F-75014, France, INSERM, U567, Paris F-75014, France, CNRS, UMR 8104, Paris F-75014, France, and Université Paris Descartes, Faculté de Médecine René Descartes, UMR-S 8104, Paris F-75014, France

Cell-surface expression and biological functions of several intracellular-retained G protein-coupled receptors are restored by membrane-permeable ligands called pharmacological chaperones. We have previously demonstrated that a mutation of the hydrophobic motif ³⁴¹FNX₂LLX₃L³⁵⁰ in the C terminus of the human pituitary vasopressin V3 receptor (MUT V3R) led to it being retained in the endoplasmic reticulum (ER). Here, we establish the precise role of this motif and investigate whether SSR149415, a non-peptide V3R antagonist, behaves as a pharmacological chaperone for the ER-retained MUT V3R. The absence of the mutated receptor in the plasma membrane is linked to its prolonged association with the molecular chaperone calnexin in the ER and to its intensive degradation by the ubiquitin-proteasomal machinery. However, this is not because of a lack of oligomerization, as demonstrated by the presence of MUT V3R homodimers in the ER. Treatment with SSR149415 restores expression of the mutated receptor on the cell surface and its correct maturation, resulting into the functional recovery of its signaling properties. SSR149415 acts by stabilizing a native-like conformation of the V3R, reducing its association with calnexin and, thus, favoring a secretory pathway rather than the proteasomal degradation pathway. In conclusion, the FN(X)₂LL(X)₃L sequence is an important motif for the V3R conformation, and the misfolding resulting from its mutation alters the receptor export but can be reverted by SSR149415.

Received for publication, September 15, 2005 , and in revised form, October 3, 2005.

^* This work was supported by INSERM, the CNRS, and the Université René Descartes and by grants from the Ligue Nationale contre le Cancer, Association pour la Recherche sur le Cancer, Fondation de France, and Société Française d'Endocrinologie. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: Institut Cochin, Département d'Endocrinologie, 24 rue du Faubourg Saint-Jacques, Paris F-75014, France. Tel.: 153732750; Fax: 153732751; E-mail: clauser{at}cochin.inserm.fr.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				X. Ge, H. H. Loh, and P.-Y. Law {micro}-Opioid Receptor Cell Surface Expression Is Regulated by Its Direct Interaction with Ribophorin I Mol. Pharmacol., June 1, 2009; 75(6): 1307 - 1316. [Abstract] [Full Text] [PDF]

				D. Yasuda, T. Okuno, T. Yokomizo, T. Hori, N. Hirota, T. Hashidate, M. Miyano, T. Shimizu, and M. Nakamura Helix 8 of leukotriene B4 type-2 receptor is required for the folding to pass the quality control in the endoplasmic reticulum FASEB J, May 1, 2009; 23(5): 1470 - 1481. [Abstract] [Full Text] [PDF]

				M. T. Duvernay, C. Dong, X. Zhang, F. Zhou, C. D. Nichols, and G. Wu Anterograde Trafficking of G Protein-Coupled Receptors: Function of the C-Terminal F(X)6LL Motif in Export from the Endoplasmic Reticulum Mol. Pharmacol., April 1, 2009; 75(4): 751 - 761. [Abstract] [Full Text] [PDF]

				H. Orcel, L. Albizu, S. Perkovska, T. Durroux, C. Mendre, H. Ansanay, B. Mouillac, and A. Rabie Differential Coupling of the Vasopressin V1b Receptor through Compartmentalization within the Plasma Membrane Mol. Pharmacol., March 1, 2009; 75(3): 637 - 647. [Abstract] [Full Text] [PDF]

				A. V. Kenny, S. L. Cousins, L. Pinho, and F. A. Stephenson The Integrity of the Glycine Co-agonist Binding Site of N-Methyl-D-aspartate Receptors Is a Functional Quality Control Checkpoint for Cell Surface Delivery J. Biol. Chem., January 2, 2009; 284(1): 324 - 333. [Abstract] [Full Text] [PDF]

				P. M. H. Markkanen and U. E. Petaja-Repo N-Glycan-mediated Quality Control in the Endoplasmic Reticulum Is Required for the Expression of Correctly Folded {delta}-Opioid Receptors at the Cell Surface J. Biol. Chem., October 24, 2008; 283(43): 29086 - 29098. [Abstract] [Full Text] [PDF]

				C. Norez, F. Bilan, A. Kitzis, Y. Mettey, and F. Becq Proteasome-Dependent Pharmacological Rescue of Cystic Fibrosis Transmembrane Conductance Regulator Revealed by Mutation of Glycine 622 J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 89 - 99. [Abstract] [Full Text] [PDF]

				A. Pena, B. Murat, M. Trueba, M. A. Ventura, G. Bertrand, L. L. Cheng, S. Stoev, H. H. Szeto, N. Wo, G. Brossard, et al. Pharmacological and Physiological Characterization of d[Leu4, Lys8]Vasopressin, the First V1b-Selective Agonist for Rat Vasopressin/Oxytocin Receptors Endocrinology, September 1, 2007; 148(9): 4136 - 4146. [Abstract] [Full Text] [PDF]

				T. T. Leskela, P. M. H. Markkanen, E. M. Pietila, J. T. Tuusa, and U. E. Petaja-Repo Opioid Receptor Pharmacological Chaperones Act by Binding and Stabilizing Newly Synthesized Receptors in the Endoplasmic Reticulum J. Biol. Chem., August 10, 2007; 282(32): 23171 - 23183. [Abstract] [Full Text] [PDF]

				C. S.-L. Gal, D. Raufaste, S. Derick, J. Blankenstein, J. Allen, B. Pouzet, M. Pascal, J. Wagnon, and M. A. Ventura Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R938 - R949. [Abstract] [Full Text] [PDF]